MaxCyte (LON:MXCT)delivered a consensus-beating 30% step up in 2019 (FY19) revenues, driven by sales of licences for its proprietary cell engineering platform and early clinical milestones from some of its eight clinical/commercial licences, reaching a five-year revenue compound annualised growth r
28 Jan 2020
MaxCyte - delivering growth, highlighting value
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
MaxCyte - delivering growth, highlighting value
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
28 Jan 2020 -
Author:
Emma Ulker -
Pages:
3
MaxCyte (LON:MXCT)delivered a consensus-beating 30% step up in 2019 (FY19) revenues, driven by sales of licences for its proprietary cell engineering platform and early clinical milestones from some of its eight clinical/commercial licences, reaching a five-year revenue compound annualised growth r